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TO THE EDITOR
T-cell immunity plays a pivotal role in chronic myelogenous leukemia (CML), as has become clear from clinical experience with allogeneic stem cell transplantation (SCT). 1 The most striking and direct evidence for the immune-mediated graft-versus-leukemia concept stems from the observation that patients with relapsed CML after allogeneic SCT can be reinduced to complete remission by infusing donor-derived peripheral blood lymphocytes. 2 In the autologous setting, leukemia reactive T cells are present. 3 However, antileukemic responses are lacking because of T-cell anergy to the CML cells. T-cell anergy to leukemic cells in CML occurs most probably because of the lack of appropriate immune costimulatory molecules. It has recently been shown that the amino-acid sequences at the fusion point of the bcr/abl translocation characteristic for CML are processed within the cell and presented by HLA molecules on the surface of leukemic cells to T cells. 4 This implies that vaccination has a sound basis and deserves further exploration. Dendritic cells (DCs) are the most potent antigen-presenting cells, possessing the unique ability to prime naïve CTL and Th cells and to break immunological tolerance. 5 The ability to generate leukemic DC from patients with CML with the potency to induce autologous T-cell proliferation in vitro, while conserving the CML-specific antigenic profile, has been shown. 6 Here, we report on the use of in vitro-generated leukemic DC for in vivo stimulation and generation of effector T cells by intradermal vaccination of IFN-resistant CML patients with autologous CML/DC.
After informed consent, three IFN-a-resistant CML patients without an HLA-identical donor were included in this protocol, which was approved by the medical ethical committee of the VU University medical center. The clinical characteristics are listed in Table 1 . Treatment was stopped 14 days before harvesting of leukocytes for vaccine preparation.
Pheripheral blood mononuclear cells (PBMCs) of patients were isolated by Lymphoprep (Nycomed, Oslo, Norway) centrifugation from a total of 160 (2 Â 80) ml of blood. CML/DC were generated by culturing PBMC (2 Â 10 6 /ml) at 371C in 5% CO 2 in 175 cm 2 tissue culture flasks (Corning Inc., Corning, NY, USA) in 25 ml of RPMI-1640 medium (GIBCO, Grand Island, NY, USA); 10% fetal calf serum (FCS) (Life Technologies, Eggenstein, Germany); 2 mM Lglutamine and 50 U/ml penicillin/streptomycin, supplemented with 100 ng/ml GM-CSF (Schering-Plough ), 10 ng/ml IL-4 (ScheringPlough ) and 2.5 ng/ml TNFa (CLB, Amsterdam, the Netherlands) for 14-21 days. The CML/DC phenotype was confirmed by flowcytometric analysis of the following markers: CD1a, CD40, CD54, CD80, CD83, CD86, and HLA-DR, as previously described. Differentiated CML/DC were harvested and concentrated to 1 Â 10 7 viable CML/DC per ml. Vaccines were not cryopreserved, but immediately administered.
The cells were pulsed with keyhole limpet hemocyanin (KLH) (50 mg/ml Perimmune, Seattle, WA, USA) for 2 h at room temperature. KLH-pulsed CML/DCs were washed once and resuspended in 0.3 ml of Hanks' balanced salt solution containing 100 ng/ml GM-CSF (Schering-Plough). The first and second vaccines were supplemented with 10 7 viable BCG particles (a kind gift of Dr A Claessen, VUMC, Amsterdam, the Netherlands). Aliquots of freshly obtained CML cells as well as cultured CML/DC were frozen for in vivo skin testing and in vitro immunomonitoring. Skin testing preparations consisted of KLH, uncultured CML, and CML-DC or monocyte-derived DC (MoDC), generated either in FCS-containing or serum-free medium (Stemspan H2000, Stem cell Technologies, Meylan, France). All vaccine and skin testing preparations were irradiated (60 Gy) prior to administration. A total of four CML/DC vaccines were administered intradermally at one-weekly intervals. All vaccinations were given in close proximity of the initial vaccination site on the right anterior thigh. At the time of first vaccination and 3 weeks after the fourth (ie last) vaccination, three skin tests were performed by intradermal injections of CML cells, CML/DC (both at 2-3 Â 10 6 per injection) and 10 mg KLH, respectively. The first series of skin test injections were made on the volar side of the right arm, the second series of the left arm, and delayed type hypersensitivity (DTH) reactions were evaluated for erythema and induration (diameter), 48 h later. 7 In patient 3, 20 months after vaccination, additional skin tests were performed with KLH, CML,CML/DC, and MoDC. T cells (pre and postvaccination) were isolated and expanded from PBMC as described previously, 8 separated into CD4+ and CD8+ T cells by magnetic microbead separation (Miltenyi, Bergisch Gladbach, Germany), and subsequently cocultured for 4 and 7 days respectively, with CML/DC, uncultured CML cells, or KLH loaded on autologous CML/DC. IFN (release was measured by ELISA 24 h after start of culture (CLB, Amsterdam, The Netherlands) and IFN (elispot assays were performed at the end of coculture as described previously.
8 KLH plasma IgG levels were measured by titration in a routine ELISA assay, as described (coating with 0.5 mg/ml KLH).
9
In vitro-generated CML/DC displayed morphological DC characteristics with a typical veiled appearance and an immature phenotype (CD40+, CD54+, CD80+, CD83À, and CD86+). They proved to be potent T-cell stimulators in the allo-MLR, while FISH analysis revealed the bcr/abl translocation, confirming their leukemic origin (data not shown).
The total number of available viable CML/DC to a maximum of 25 million was administered per vaccination (patient 1: 25 million for vaccine nos. 1-4; patient 2: 13.8, 6.8, 25, 25 million for vaccine nos.1-4, respectively; patient 3: 4.3, 5.6, 4.5, 6.0 million CML/DC for vaccine nos. 1-4, respectively). No adverse events after vaccination were noted except for local pain and mild induration in all, while only in patient 2 ulceration at the site of the first two intradermal vaccinations was observed. No clinical signs of autoimmune diseases were detected after a median follow-up of 21 months. Hematological or cytogenetic responses were not achieved. AntiKLH IgG antibodies ( Figure 1a) were detected following vaccination with KLH-pulsed CML/DC indicating that the immune system of the patients could mount an immune response against a neoantigen presented by the CML/DC.
No DTH reaction against uncultured CML cells, KLH, or CML/DC was detectable prior to vaccination. After four cycles of vaccination in all patients, a strong DTH against KLH was demonstrated, indicating the generation of KLH-specific memory T cells (Figure 1b) . In patients 2 and 3, strong DTH reactions against CML/DC and uncultured autologous CML cells were observed (Figure 1b+c) .
Owing to the high tumor burden of these patients, nonmalignant DC could not be generated to serve as leukemia specificity controls in the skin tests. Subsequent to vaccination, patient 3 reached a complete cytogenetic response upon treatment with Imatinab (Glivec). This allowed for the generation of nonmalignant MoDC for a head-to-head comparison in skin tests with CML/DC, generated from cryopreserved CML. Results showed a persistent reactivity to KLH, CML-DC, and CML, 20 months after the last vaccination (Figure 1b ) At this time a weak, but persistent leukemia-specific response could be demonstrated (Figure 1d) .
We detected low, but elevated levels of IFNg release by CD4+ Th cells in response to CML after vaccination (mean IFNg release per million Th cells per 24 h: 13.3 pg/ml (range: 0-40 pg/ml) prevaccination; 85.3 pg/ml (range: 8-204 pg/ml) post-vaccination). This was paralleled by a slight increase in the frequency of IFNg-producing Th cells responding to CML in the elispot assay (mean IFNgproducing Th cells/100 000: 13.0 (range: 0.7-37.0) prevaccination; 40.4 (range 39.0-48.2) postvaccination). Similar IFNg Th response levels were observed against CML and CML/DC in these assays, but no KLH-specific response could be detected. No increase in the frequency of IFNg-producing CD8+ CTL in the elispot assay in response to either CML or CML/DC was observed after vaccination.
With this small-scale phase I study, we have shown that intradermal vaccination with in vitro generated autologous CML/ DC in patients with late chronic phase CML is feasible, without adverse side effects. It proved possible to mount an immune response in these pretreated patients, as demonstrated by the strong DTH reaction against KLH. Most promising was the finding in 2/3 patients of a DTH reaction against autologous CML/DC and uncultured CML cells and in one of these patients of a measurable leukemia-specific response up to 20 months after the last vaccination. It is remarkable that in the presence of such a large tumor burden, an appreciable antileukemia immune response could be induced. Accrual for this study was stopped prematurely because of the availability of the very effective bcr/abl-specific tyrosine kinase inhibitor STI571 (Gleevec) for IFN-a-resistant CML. 10 However, the majority of CML patients who achieve complete cytogenetic responses after STI are still bcr/abl PCR positive, 11 indicating the presence of minimal residual disease (MRD). Also, the emergence of resistance mechanisms against STI571 has been reported. 12 Therefore, adjuvant immunotherapy is still a viable option in the management of CML, particularly in patients with MRD after STI571 treatment. Our study indicates that autologous CML/DCbased vaccination may be a valid approach in this regard. 
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